Menu
Not yet recruiting NCT07725614

Nasal Cannula Versus Single Nasal Prong for Non-Invasive Ventilation in Preterm Infants

No phase Interventional Prematurity

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Experimental, Intervention Name: Nasal Cannula, Active comparator: single nasal prong.
Who it may be relevant to
Registry conditions: Prematurity. Basic parameters: 0 Minutes — 6 Hours · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Indonesia
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Nasal Cannula Versus Single Nasal Prong for Non-Invasive Ventilation in Preterm Infants After Birth: A Randomized Controlled Trial

Overview

Preterm infants frequently require non-invasive ventilation (NIV) to treat respiratory distress after birth. The effectiveness of NIV may be influenced by the interface used to deliver respiratory support. Nasal cannula and single nasal prong are two interfaces commonly used for NIV; however, evidence directly comparing their efficacy during the early postnatal period remains limited. This randomized controlled trial aims to compare the efficacy of a nasal cannula and a single nasal prong as interfaces for non-invasive ventilation in preterm infants after birth. Eligible preterm infants requiring NIV after initial stabilization will be randomly assigned to receive respiratory support using either a nasal cannula or a single nasal prong. The assigned interface will be maintained for one hour following randomization, including during transport from the delivery room to the neonatal intensive care unit. The primary outcome is the need for endotracheal intubation within one hour after interface application. Secondary outcomes include the need for endotracheal intubation within 6 hour of age, respiratory effectiveness, assessed by the oxygen saturation index (OSI) and arterial blood gas parameters (pH and partial pressure of carbon dioxide \[pCO₂\]), as well as interface-related adverse events, including interface dislodgement and nasal injury. This study is expected to provide evidence to support the selection of an effective non-invasive ventilation interface for preterm infants after birth.

Interventions

  • Device Experimental, Intervention Name: Nasal Cannula
    Non-invasive ventilation delivered through a nasal cannula as the respiratory interface for one hour after randomization in preterm infants after birth.
  • Device Active comparator: single nasal prong
    Non-invasive ventilation delivered through a single nasal prong as the respiratory interface for one hour after randomization in preterm infants after birth.

Primary outcome measures

  • The need for endotracheal intubation [Time frame: Within 1 hour after interface application.]
Secondary outcome measures (6)
  • The need for Endotracheal Intubation [Time frame: By 6 hours of age]
  • Oxygen Saturation Index (OSI) [Time frame: At 1 hour after interface application]
  • Partial Pressure of Carbon Dioxide (pCO₂) [Time frame: At 1 hour after interface application]
  • Blood pH [Time frame: At 1 hour after interface application]
  • Interface Dislodgement [Time frame: Within 1 hour after interface application]
  • Title Nasal Injury [Time frame: At 1 hour after interface application]

Eligibility criteria

Inclusion criteria

Inclusion criteria

  • Preterm infants with a gestational age of 28 to <37 weeks who develop respiratory distress and require non-invasive ventilation (NIV) after birth.
  • Written informed consent is obtained from a parent or legal guardian.

Exclusion criteria

  • Infants with congenital nasal defects, including cleft lip and palate.
  • Infants with prenatally diagnosed congenital anomalies that contraindicate NIV, including congenital diaphragmatic hernia, choanal atresia, esophageal atresia with tracheoesophageal fistula, or congenital heart disease.
  • Infants with multiple congenital anomalies.
  • Infants requiring endotracheal intubation for positive pressure ventilation immediately after birth.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

Indonesia · 1 center
  • Rumah Sakit dr. Cipto Mangunkusumo — Jakarta

Identifiers

NCT: NCT07725614 · 26-02-0251

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗